マイルストーン・サイエンティフィック（MLSS）2026年第2四半期決算説明会：売上高22%増、ガイダンスを維持

要点

• 2026年第2四半期の売上高は前年同期比22%増の280万ドルとなり、上半期の売上高は9.8%増の500万ドルとなりました。
• CompuFloの初期段階の導入拡大に支えられ、医療部門の売上高は2025年第2四半期から231%増加しました。
• 第2四半期の売上総利益率は、製品および顧客構成、関税、一部の輸入製品や部品のコスト上昇の影響を反映し、69.6%から67.2%に低下しました。
• 同社は2026年通期の売上高見通し（980万ドル〜1020万ドル）を再確認しました。経営陣は、年内の残り期間においてCompuFloの成長率がビジネス全体を上回ると見込んでいます。
• 経営陣は、夏季の通常見られる季節変動や、第2四半期に寄与した2件の海外大型歯科注文が一巡することを挙げ、第3四半期の売上高を230万ドル〜250万ドルと予想しました。
• 経営陣によると、NovitasおよびFirst Coastの料金表のもと、3つの管轄区域と13州（全米人口の約30%〜35%に相当）で325ドルのメディケア支払額が設定されました。

主な財務業績

2026年6月30日時点で、マイルストーン・サイエンティフィックの現金および現金同等物は210万ドル、運転資本は370万ドル、未償還の転換社債は46万6,000ドルでした。同社は4月に完了した251万ドルの第三者割当増資（パイプ）による調達資金で事業運営を継続しており、現時点で追加の資金調達は計画していないと述べています。

事業およびオペレーションの業績

CompuFloは初期の商業的牽引力を獲得し続けています。医療提供者は、NovitasおよびFirst Coastの管轄区域で好ましいメディケア支払結果を得ているほか、人身傷害保護や労災保険プランを含む民間保険会社からの支払も受けています。

マイルストーン・サイエンティフィックは、対象地域において3社の販売パートナーとともに直販展開を開始する計画です。また、同社はPalmettoと協力しており、西部に事業を拡大するにつれてCGS、WPS、およびNoridianへのアプローチを進める方針です。

Operative Neurosurgery誌に掲載されたテキサス大学医学部の査読付き研究によると、脊髄刺激装置の植込み時におけるCompuFloガイド下の硬膜外アクセスは、複合的な合併症のオッズを91%減少させることが示されました。経営陣は、CompuFloが世界中の40を超える大学、学術医療センター、教育病院で評価または使用されていると述べました。

四半期末以降、マイルストーン・サイエンティフィックはRed One Medicalと販売代理店契約を締結し、退役軍人省、国防総省、国防保健局、インディアン健康サービスなどの米連邦政府ヘルスケア機関の顧客獲得を目指しています。同契約に最低購入義務はありません。各機関が同スケジュールを通じて発注を開始するには、まず製品を連邦供給スケジュール（FSS）に追加する必要があり、経営陣は2026年第4四半期の初回受注を目指しています。

歯科部門では、同社は全米規模の販売パートナーを新たに追加し、海外展開を拡大し続けました。最近、ウズベキスタンで登録承認を取得したほか、今後の四半期で日本、メキシコ、トルコ、インドでの登録を目指しています。第2四半期の売上上振れのうち約50万ドルは、海外からの大型歯科注文によるものでした。

同社はまた、製品の質問への回答、教育情報の提供、見込み客のスクリーニング、医療従事者と営業・サポートチームの接続を目的として設計されたAI搭載デジタルエンゲージメントプラットフォーム「Milo」を試行導入しました。デジタルキャンペーンにより月間約150〜200件の見込み客が獲得されたほか、ASPN 2026カンファレンスからは40件以上の有望な見込み客が獲得されました。

経営陣の見通し

マイルストーン・サイエンティフィックは、前年比2桁成長となる2026年通期の売上高見通し（980万ドル〜1020万ドル）を再確認しました。経営陣は、2026年の残り期間においてCompuFloの売上成長率がビジネス全体を上回ると見込んでいます。

2026年第3四半期について、経営陣は売上高を230万ドル〜250万ドルと予想しています。前四半期比での減少予測は、大型の海外注文2件の一巡および夏季の季節的な需要減速を反映したものです。

経営陣は、メディケア償還対象の拡大や直販の開始を含む医療部門の取り組みが、2026年下半期により本格的な貢献をもたらすと期待しています。

リスクと注視点

• 第2四半期の売上総利益率は、製品および顧客構成、関税、輸入製品や部品のコスト上昇によって圧迫されました。
• 2件の大型海外歯科注文が第2四半期の業績を押し上げましたが、第3四半期には再発しない（一巡する）見込みです。
• 経営陣は、第3四半期について夏季にあたるため季節的に需要が減速する四半期であると説明しました。
• 医療分野での商業化は依然として初期段階にあり、適切な保険請求や追加のメディケア事務受託業者（MAC）管轄区域への拡大に一部依存しています。
• 同社は、医療商業化組織における人員制約を認め、現在獲得している見込み客（リード）のボリュームがフォローアップ能力を超えていると述べました。
• Red One Medicalを通じた機会は、受注が開始される前に連邦供給スケジュール（FSS）の要件を完了することに依存しています。

アナリスト質疑応答のハイライト

経営陣によると、NovitasとFirst Coastは現在3つの管轄区域と13州をカバーしています。同社はPalmettoと連携しており、追加のメディケア事務受託業者の獲得を目指していますが、フロリダ州および既存のNovitas市場での商業的実行力を確立した上で、計画的に拡大していく意向です。

CompuFloアドバイザープログラムには約10〜11名の医師アドバイザーが参加しています。短期的取り組みはアドバイザーの募集から、追加管轄区域での保険請求申請および償還制度の開拓へと移行しつつあります。

見込み客のボリュームに対応するため、マイルストーン・サイエンティフィックはフォローアップ専用の従業員を2名増員すると同時に、Miloを活用してデジタルエンゲージメントと見込み客の絞り込みを支援する計画です。経営陣は、医療および歯科キャンペーンが引き続き強い問い合わせを生み出していると述べました。

同社は、複数の地域販売代理店とマイルストーン自社の営業統括チームを組み合わせる計画です。代理店が臨床上の専門知識と販売エリアのカバーを提供し、社内スタッフが実施管理と価格設定を担当します。初期の重点市場にはフロリダ州が含まれ、続いてニュージャージー州、ペンシルベニア州、テキサス州が対象となります。

決算説明会全文文字起こし

決算説明会の完全なトランスクリプト

経営陣による説明

Operator

Greetings. Welcome to the Milestone Scientific Second Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, James Carbonara with Hayden IR.

James Carbonara

Thank you, operator. Before we begin, please note that today's call will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Please refer to our earnings release as well as our filings with the SEC, including our 2025 Form 10-K for a discussion of these risks. A replay of this call will be available shortly after its conclusion. With that, I'll turn the call over to our CEO, Eric Hines.

Eric Hines

Thank you, James, and good morning, everybody, and thank you for joining our call today. Our second quarter results reflect continued execution of the strategy we laid out at the start of the year, disciplined cost management and focused investment in our highest growth opportunities. Total revenue for the second quarter was $2.8 million, an increase of 22% compared to the second quarter of 2025, bringing our first half revenue to $5 million, up nearly 10% year-over-year. Our base business performed very well, contributing $2.4 million in the quarter, further supported by approximately $500,000 in upside from international orders.

In the Medical business, CompuFlo continued to build momentum with Medical segment revenue growing 231% compared to the second quarter of last year. While medical is still growing from a small base, there is real validation of the technology's value proposition, and we continue to scale the CompuFlo Advisor program launched in February, adding physician advisers and expanding procedural use across additional Milestone Administrative Contractor jurisdictions and commercial payers.

On the reimbursement front, our health care providers are actively submitting claims and have received favorable payment outcomes from Medicare in the Novitas and First Coast jurisdictions as well as from commercial payers, which includes personal injury protection and workers' compensation plans. We currently have established $325 payment established under Novitas and First Coast fee schedules covering 3 regions and 13 states, and we're continuing to pursue the remaining MACs.

Alongside our 3 distribution partners in these areas, we plan to begin launching direct sales efforts in each region starting immediately. We also achieved an important milestone of third-party validation this quarter following the publication of the peer-reviewed University of Texas Medical Branch study in Operative Neurosurgery, which associated CompuFlo-guided epidural access during spinal cord stimulator implantation with a 91% reduction in the odds of composite complications.

The compelling evidence reinforces CompuFlo's differentiated value proposition and supports growing physician acceptance and expanded utilization across critical, spinal and epidural procedures, including epidural steroid injections, spinal cord stimulator implantation, obstetric epidurals, thoracic and cervical epidurals, neuromodulation therapies and surgical epidural anesthesia. CompuFlo has now been evaluated or utilized across more than 40 universities, academic medical centers and teaching hospitals worldwide.

Subsequent to quarter end, we expanded the addressable market for CompuFlo with a strategic distribution agreement with Red One Medical, an established federal health care distributor to bring CompuFlo to the U.S. Department of Veterans Affairs, Department of Defense, Defense Health Agency, Indian Health Service and other federal health care organizations, systems that collectively serve more than 18 million enrolled veterans and military beneficiaries. We believe this partnership gives us an efficient pathway into one of the largest and most strategically important health care markets in the country.

On the dental side, we signed a new national distribution partner to expand our sales network and complement our e-commerce business, and we continue to build on our international footprint with a recent registration approval in Uzbekistan and additional registrations targeted in Japan, Mexico, Turkey and India in the coming quarters. We also launched the first phase of our AI strategy this quarter with a pilot debut of Milo, our AI-enabled digital engagement platform at the ASPN 2026 Conference in Miami Beach.

Milo is designed to answer product questions, provide educational information, support lead qualification and connect health care professionals with our sales, clinical and customer support teams, helping us engage prospective customers on their own time, which we believe unlocks a meaningful opportunity with small commercial teams. ASPN was also a strong show and commercially, generating more than 40 qualified leads and it marked the launch of our #NoWetTaps campaign, building on the complication reduction data we're seeing with CompuFlo.

In terms of governance, we strengthened our Board of Directors with Benedetta Casamento transitioning from Chair to Executive Chair and the addition of 2 new independent directors, Greg Schilling and Kelly Ann Ulto, who bring additional health care, technology, finance and governance expertise. Turning to our capital position. We continue to operate from the $2.51 million private placement we completed in April. We are not currently planning to raise additional capital and continue to evaluate incremental sources as our net operating loss carryforwards and R&D tax credits programs and remain focused on funding the business through the disciplined execution that was meaningfully narrowed our losses over the past year.

We are reaffirming our 2026 guidance of $9.8 million to $10.2 million in total revenue representing double-digit growth for the year, with CompuFlo expected to grow at a faster rate than the overall business for the remainder of 2026. I do want to set expectations appropriately for the third quarter. Our second quarter benefited from 2 large international orders that we don't expect to recur in the third quarter. And the third quarter is typically a seasonally slower period for us given the summer months.

Please keep that in mind as you model the quarter. That said, we expect our medical initiatives, including our expanding Medicare reimbursement footprint and the direct sales launch we are now making alongside our distribution partners to continue building and to contribute more meaningfully to the second half of the year. And we'll provide more detail on the trajectory alongside of our third quarter results in November. I'll now turn the call over to Keisha to review our financials. Keisha?

Keisha Harcum

Thank you, Eric, and good morning, everyone. For the 3 months ending June 30, 2026, total revenue was $2.8 million compared to approximately $2.3 million for the same period in 2025, representing an increase of approximately $518,000 or 22%. The increase in total net sales was driven by the growth in the dental product sales and continued early stage of adoption of commercialization of the company's medical products.

Gross profit for the 3 months ended June 30, 2026, was $1.9 million compared to $1.6 million in the prior year period. Gross margin was 67.2% for the 3 months ending June 30, 2026, compared to 69.6% for the same period. The decrease in gross margin was primarily due to the product and customer mix and increased product costs, including tariffs and tolls and certain import products and components. These cost pressures were partially offset by higher levels of sales during the current period.

Operating expenses decreased by approximately $0.5 million or 4.2% to approximately $3 million for the 3 months ending June 30, 2026, compared with approximately $3.1 million for the 3 months ending June 30, 2025. The decrease was primarily attributable to the lowered quality and regulatory expenses, consulting, professional fees, research and development, rent, occupational costs and other segments. Net loss was $1.1 million or negative [indiscernible] per share compared to the net loss of $1.5 million.

For the 6 months ending June 30, 2026 and '25, the total revenue was $5 million and $4.6 million, respectively, an increase of $447,000 or 9.8%. Gross profit for the 6 months ending June 30, 2026, was $3.5 million or 69.4% of revenue compared to $3.3 million or 71% of revenue. Operating expenses decreased by approximately $1.4 million or 20% to approximately $5.4 million for the 6 months ended June 30, 2026, compared to approximately $6.7 million for the 6 months ending June 30, 2025.

Net loss...

Eric Hines

Did we lose you, Keisha?

Keisha Harcum

Yes. No, I'm sorry, the phone clicked. As of June 30, 2026, the company had cash and cash equivalents of $2.1 million and working capital of $3.7 million and $466,000 in convertible outstanding debt. At this time, I'll turn it back over to Eric.

Eric Hines

All right. Thanks, Keisha. So I want to first and foremost, thank everyone who wished me my 1-year anniversary date, which was August 1, 2026. So thank you to those who have reached out to me. What I can say about the company is we are 180 degrees different than when I joined the company. And I say that since we've added a lot of great employees and doing a lot of great things and a lot of great programs that are in place. And I'll leave the group here with, first of all, thank you for being shareholders, and thank you for being interested in Milestone, and thank you for your support. But most of all, I think our best chapters are ahead of us. So thank you, and we'll turn the call over to questions at this point.

Operator

[Operator Instructions] Your first question for today is from Bruce Jackson with StoneX.

質疑応答

Bruce Jackson

Congrats on the quarter. So I just wanted to clarify from the press release, how many MACs do you currently have that are -- have the reimbursement in place? And then do you anticipate adding any more and when?

Eric Hines

So we have 2 MACs, which cover 3 jurisdictions and 13 states. So those are Novitas and First Coast, and we will be adding more MACs along the way. We're currently working very closely with Palmetto, and then we'll move to an extent Westward and start to collect CGS and WPS and Noridian. So we've got 2 currently with 3 jurisdictions in 13 states, representing about 30% to 35% of the population.

Bruce Jackson

Okay. Great. And then I just want to be clear on the sales guide for the third quarter. So it's going to be down sequentially, but I'm just trying to kind of gauge how much it's going to be down from the second quarter.

Eric Hines

Right now, we're projecting, again, I would say, in the range of $2.3 million to $2.5 million would be the range that I would provide.

Bruce Jackson

Okay. And then the last question I want to ask was in the press release, you mentioned a study where use of CompuFlo reduced composite complications, which I thought was pretty interesting. Can you kind of discuss a little bit why that is?

Eric Hines

Just because of the number of, I guess, sometimes posts that they have to do. So for instance, with the accuracy that we command with the CompuFlo, they can get much more precise as far as where they're doing the implant. And so a lot of times, they'll have multiple sticks, if you will, that they have to go through with a traditional LOR syringe. And using CompuFlo within that study, they were able to reduce the missteps or the misplacement by significant amounts.

Operator

Your next question for today is from Tom McGovern with Maxim Group.

Thomas McGovern

Yes. First question is on the adviser program. So as of the last update in 1Q, you guys reported 8 active physician partners and you had 6 pending. I'm just curious if you could give an update. I'm sorry if I missed it earlier in the prepared remarks, but just curious where that's at currently.

Eric Hines

Yes. We've added a few more. I think we're up to maybe 10 or 11. We're not really actively adding more advisers at this point as we're looking to get -- focusing on the claim submission. The claim submission is really what drives the reimbursement. And now that we've completed that exercise to an extent with Novitas and First Coast, we're turning our jets to other MACs. So the adviser program was really put in place to get people using the product to start submitting claims to get feedback and to get the Medicare reimbursement back in place.

Now we're moving into Palmetto and out West with a few of the other MACs that we'll start adding advisers out in those areas. So we're limited by -- a little bit by the scale. We've only got a couple of people working on the medical front right now. That's going to be changing here quite dramatically here in the next several weeks, but we're limited by the capacity of the staff.

Thomas McGovern

Understood. I appreciate that color. Next question, again, back in 1Q, you guys gave us some encouraging news with the digital marketing campaign. It has contributed to 20 to 30 leads per week. I was wondering if that run rate or that rate had sustained into 2Q and what your conversion rate on those leads from Q1 was?

Eric Hines

Yes. So the campaign has continued to do extremely well, getting anywhere between 150 to 200 leads per month. Again, we're sort of at a capacity situation where -- and that's why we launched Milo, which is going to be the AI bot that helps sort of prosecute some of those leads while they're on the phone and because we just don't have enough people to frankly follow up. And so the leads continue to grow to a point that we need to add people to handle them. In fact, we're getting ready to bring on 2 additional people that all they will do is follow up on the leads because the campaigns have generated such demand that we need to find a better way to keep up with them. Milo is one of them and then resources are another.

So as compared to the Q1, the leads continue to be just as high, if not higher, and especially now that we've sort of added medical to that cadence. And so it's not just the dental leads, it's hundreds of medical leads, including the great showing that we had at ASPN, where I would argue that we were the most attended booth in the entire event. So we're not short of leads.

Thomas McGovern

Got it. Got it. And then final question for me is just on the Red One Medical distribution agreement. I'm just trying to understand a little bit about the structure. Are there any minimum purchase or stocking commitments through this agreement? And then if you're still working on sending out the first order, how does that contracting work between the VA and DoD, is that all preapproved? Or are you guys going to have to maybe negotiate separate contracts with each channel or each subchannel rather?

Eric Hines

No, it will be on the price schedule. It will be on the FSS schedule, and we're still working through that. So we've got the agreement in place with Red One. There's no minimum commitments. I mean I think you probably know that they're a very recognized national brand in the veteran space. So we've already -- we're already targeting business just out of the gate. But again, we're still waiting for some of the details to be added to the FSS schedule. And then once that's in place, everyone will buy off that schedule versus us having to go through negotiations with each of the individual agencies.

Thomas McGovern

Sure. And just for our understanding, I understand that could be a little bit of a drawn out process as anything with the government. But just curious, internally, what are you guys looking at in terms of a time line to kind of work through that initial, I guess, like logistical or contracting push and transition to orders?

Eric Hines

Yes. We -- our goal is to be taking orders in Q4.

Operator

Your next question for today is from [ John Korb ], a private investor.

Unknown Attendee

Eric, nice to be with you this morning. You said in your comments that this company is 180 degrees different than it was a year ago. Congratulations on your 1 year. Had you not said that, I certainly got that sense from reading the quarterly report that I just finished reading. It's without a doubt the most comprehensive and hopeful quarterly report I've ever read for Milestone. I really feel like we get some traction here with Milestone and your ability to grow this company is very helpful for me.

I have one question regarding Red Medical and any distributor. In the past, especially with the dental, distributors would be signed up, and that's all that the distributor, nothing happened. What is the distributor agreement? What do they do? Do they sell? Do they just facilitate -- with any distributorship you have in anywhere domestically or internationally, what agreement do you have with them and from them?

Eric Hines

So we control the pricing with the distributors versus some other ways of going to market where they're allowed to discount up to a certain amount. So we want to make sure that we have cost control for, I guess, a starting point. So -- and then they obviously get points on the sales. The distributors, the way that they'll work for us, for instance, in Florida is they will act not only as additional feet on the street, but they will also -- they've got a lot of technical expertise, right? So again, we're a little bit constrained from a resource perspective. So the distributors will act as our clinical specialists in some cases, they'll act as our salespeople in some cases.

And then we will have some sort of hunters in Florida, and then we will also have sort of a strategic rep that will sort of manage that whole group, right? So we'll have a strong medical technology salesperson who will work with the distributors, work with the hunting team and sort of chase the business in, for instance, the state of Florida, then we will sort of rinse and repeat and do that in New Jersey, Pennsylvania and Texas here over the course of the next handful of months.

So they really just serve as -- and we have -- we'll have multiple distributors in each state. It's not -- we're not going to just hang our hat on one single distributor. We may have 2 or 3 different distributors covering the different parts of Florida, West, East and North Florida, for instance. And that gives us technical expertise, feet on the street and then having a single point of contact or 2 that are actually Milestone employees that are overseeing that and being compensated for the efficacy of the distributorships as well as their own sales.

Operator

[Operator Instructions] Your next question for today is from [ Gary Carroll ], a private investor.

Unknown Attendee

I wish you get me up so early for these calls, but I just want to say congratulations on where we are today versus where we are 1 year ago and you stepped into this mess. And sorry, I missed your anniversary. I think I was too busy trying to recruit some reps for you. But at any rate, I think the report was fantastic. I think we're moving in the right direction.

So I think some investors that have been here a long time like myself, and I've gotten some feedback from other people saying, can you ask Eric to elaborate a little bit on where we are today versus where we are exactly 2 years ago at the ASPN meeting, by the way, when we first got Medicare approval and the previous regime, I don't want to mention his name because I might get sick, took that and did nothing.

So we got reimbursement and we got no follow-through. And I think there's a big difference happening now because, obviously, we and you realize the importance that now that we have that, we have to run with that code and start submitting and I know we already are submitting cases into First Coast here in Florida, of course, which is my location and my interest.

So do we actually have a group or some -- that group in Tampa? I think we had some guys in Tampa that really helped us submit -- resubmit the cases that we needed to get Evelyn to be able to get us back to where we are today that now we can run with them all. So from your point of view, what's the difference? Because I know you've been here also during that time with Arjan. So where are we today in your mind versus where we were then because I think a lot of people want to know, we got it now. We're going to get this done. And can you shed a little light on where you think we're -- the difference?

Eric Hines

Yes. So I mean I don't really know exactly what happened prior. I mean I was a shareholder like all of us were back then, but I didn't pay too much attention, but I paid enough attention to understand that something didn't seem like it was going in the right direction. So I think the difference now is that we've sort of done it a little bit more systematically. So we've gone, I guess, a little bit -- sometimes they say you got to go slower to go faster. And I'm a big believer in that. And so we've put things in place as far as reimbursement teams to help the medical offices to prosecute the claims. That's a big help.

And we've -- now we're putting a team in the state of Florida, which will be 4 or 5 people that are just solely going after the CompuFlo business and doing it sort of in a much more methodical way. So I think really, it's just -- quite honestly, it's not spraying and praying and hoping and putting CompuFlo all over the map and all over the world, quite frankly, it's focus and it's focused on getting it right and getting the right systems and processes in place and it's replicating it across the rest of the country.

So I wouldn't anticipate that we're going full force and adding and adding MAC until we get -- show that we've had a lot of success in Florida. Now we'll obviously move into the Novitas regions with Texas and Pennsylvania and New Jersey. But we're going to do it systematically. We're going to do it with the right programs in place to support the offices and the office managers. And so I think that's really just -- it's kind of subtle, but it's going a little bit slower to make sure that we can accelerate once we get to a critical mass.

Unknown Attendee

Along that line, Eric, are we going to have specific people trained to go into -- for instance, you know I'm down in Southeast Florida, and we're getting excited about getting this thing launched. Are we going to have a support person or people that will come in and train the office staff on how these claims have to be submitted because I think there has to be some justification, if I'm correct, on the doctor using the CompuFlo, for instance, in a very difficult cervical case. It's an elderly patient with a lot of arthritis. There has to be something that goes along with that claim, correct?

Eric Hines

There does, right? I mean it has to be coded properly, all the i's dotted and t's crossed. It's actually a really good idea. So I just wrote it down about providing some training. And we've got Evelyn and her entire group with -- she's with a new company called [indiscernible], which has many, many resources, and they spend their life in getting products approved and working through that process. So I jotted that down, but I think it makes a lot of sense because we're doing a little bit of that, but we probably need to do more.

Unknown Attendee

Well, I think so because if we have the reps going in and they're getting the account, the doc wants to use it, he's excited, we get it in, we get an order, we start using it. Well, if that rep has to stop then and take time to go train the office staff or the billing people, that's going to slow down the process of the sales process. So if we have that backup of somebody supporting us with what you just said, the billing and claims and training those people, first of all, they're going to get paid a lot quicker and they're going to submit it correctly, and we're going to get what we need as far as the tracking for these cases to be tracked.

Eric Hines

100%. We're on the same page.

Unknown Attendee

I think that's -- what else -- I had something else to ask you, but now -- so now we have -- we got to a group in Tampa. Those guys that helped us are still submitting, correct? So we still got users, regular users that helped us get through that are still submitting cases.

Eric Hines

Yes.

Unknown Attendee

That's important, right? We want to keep that -- we got to keep it flowing.

Eric Hines

No doubt...

Unknown Attendee

Hang out. On that $500,000 international order, was that a big dental order that came in, by the way?

Eric Hines

Yes.

Unknown Attendee

Okay. So we're not really planning on that recurring for this quarter, as you just stated.

Eric Hines

Not at this point, no. That was...

Unknown Attendee

All right. Well, I know it's getting to be -- it's going to be 9:00 here. Listen, congratulations again. I think a lot of us -- most of us are very excited at your progress. I think you're putting a good team together. Jason, Josh, they're working hard. Josh is doing a great job down in Florida. I think we might have somebody new down in Florida soon according to what I'm hearing, which will be fantastic to get us rolling. You know this is the biggest territory in the country, buddy. So we can get this going. I think we're going to be in good shape.

Eric Hines

We appreciate your support, Gary.

Operator

We have reached the end of the question-and-answer session, and I will now turn the call over to Eric Hines for closing remarks.

Eric Hines

No. Just once again, thanks, everybody. It was a good quarter. We plan on having more good quarters. That's the plan. And I can't thank you enough for your support along the way, and we will be in touch. Thank you. Have a good day.

Operator

This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.